Abstract
Objective To investigate and analyze the effects of the infarct volume on cytokines and immune status in patients with acute ischemic stroke.
Methods Patients with acute ischemic stroke that presented within 72 h of onset from October 2017 to October 2019 were enrolled. Patients with severe cerebral infarction (large-area cerebral infarction) (n=34) were enrolled and categorized as group A; Additionally, 33 patients with non-large-area cerebral infarction with matching baseline characteristics (sex and age) to group A were included in group B. We measured IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α, and IFN-γ levels in serum using a cytometric bead array.In addition,we compared the absolute value of lymphocytes (LYM#), lymphocyte percentage (LYM%), neutrophil/lymphocyte ratio (NLR), cytokine levels, and immune status indicators (IFN-γ IL-4 ratio, TNF-α/IL-4 ratio, and TNF-α/IL-10 ratio) between groups A and B, and evaluated the effect of infarct size on inflammatory factors and immune status.
Results Compared with group B, the LYM# and LYM% in group A were significantly lower, and the NLR and cytokines (IL-2, IL-4, IL-6, IL-10, IL-17A, TNF-α, and IFN-γ) levels were significantly higher. TNF-α/IL-4 ratio was significantly lower, and the IFN-γ/IL-4 ratio (P=0.09) and TNF-α/IL-10 ratio (P=0.146) in group A demonstrated a decreasing trend although not significant.
Conclusions The immune status of patients with acute cerebral infarction is related to the infarct volume; patients with large-area cerebral infarction are more likely to develop immunosuppression.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT03335111
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Ethics Committee of the First Hospital of Jilin University reviewed and approved the study
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: wanglj66{at}jlu.edu.cn(W.Lj)
